


Supplementary Figure 1. Forest plots comparing overall survival (A) and progression-free survival (B) in patients harboring *STK11*, *KEAP1* or *CDKN2A/B* mutations according to treatment regimen (CIT or chemotherapy). CIT: cancer immunotherapy; HR: hazard ratio.

A



B

